Drug intelligence / Profile preview

BIO-10901

Development stage: Preclinical
Lead developer: BioMarck Pharmaceuticals
Modality: Peptides
Administration: Inhalation

Overview

BIO-10901 is a peptide-based therapeutic developed by BioMarck Pharmaceuticals for the treatment of Acute Lung Injury (ALI). It is part of a platform of patent-protected peptides designed to inhibit the Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) protein. MARCKS is a critical component of the inflammatory process, particularly in the lungs, where it regulates neutrophil aggregation, migration, and the release of pro-inflammatory cytokines. By targeting MARCKS, BIO-10901 aims to modulate the excessive inflammatory response and reduce the pulmonary damage associated with ALI. While BioMarck's lead compound (BIO-11006) is focused on COPD, BIO-10901 is specifically positioned for acute pulmonary inflammatory conditions.

Targets

MARCKS (Myristoylated alanine-rich protein kinase C substrate)

Beyond the preview

Go deeper on BIO-10901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-10901.

Explore the full profile